Celltrion today announced that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is approved ...

The drugmaker will use the new facility as a pipeline for existing and new product manufacturing, including biosimilars ...

Celltrion's asthma treatment is one step closer to a Canadian release, the drugmaker said Monday. The nation has greenlit Omlyclo — a biosimilar of, or lower-cost alternative to Novartis's Xolair — to ...

Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat ...

South Korean biopharmaceutical firm Celltrion announced Thursday that its third plant in Songdo, Incheon, has officially ...

South Korean biopharmaceutical firm Celltrion said Monday that it has received approval from Health Canada for Omlyclo, its omalizumab biosimilar referencing Xolair, designed to treat allergic asthma ...

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of ...

The association between untreated infertility and SARD persisted in analyses restricted to women aged < 38 years and those ...

SEOUL, Nov. 27 (Yonhap) -- South Korean drugmaker Celltrion Inc. plans to achieve annual sales of 5 trillion won (US$3.58 ...

Celltrion’s Truxima, a biosimilar of Roche’s cancer drug rituximab, and Herzuma referring to the Swiss firm’s breast cancer drug Herceptin (trastuzumab) have also got the lion’s share of ...

South Korea's antitrust regulator on Tuesday said it has fined leading drugmaker Celltrion 435 million won ($309,900) for ...